Please upgrade your browser.
Two threats in particular put reform at risk: conflicting doctrines (regarding the creation of a new public insurance option and government support for comparative-effectiveness studies) and opposition to change among some current stakeholders.
Agennix announced today that talactoferrin alfa (talactoferrin) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent(R) - Pfizer).
University Park, Pa. Over its initial six years, the Penn State Lift For Life has grown tremendously. Last year, more than 90 Nittany Lion football student-athletes tested their strength and endurance in an 11-event strength and conditioning challenge that raised more than $70,000 for the Kidney Cancer Association.
Patients with melanoma or renal cell cancer must have previously received high-dose aldesleukin AND have either progressive or recurrent disease.
Pfizer Inc has announced an innovative patient assistance program to help eligible unemployed Americans and their families who have lost their health insurance maintain access to their Pfizer medicines at no cost. Over 70 Pfizer primary care medicines are available through the program. For more information, call 1-866-706-2400.
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting. Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations.
"They said, 'Will you sing?' So I said, 'Yes, because it's for a good cause and we want to raise awareness about kidney cancer.
Physicians should review a patient's CT imaging history and cumulative radiation dose when considering whether to perform another CT exam.
Tens of millions of Americans would lose their current health insurance and could also lose their current doctors, President Obama's reassurances notwithstanding. Since there aren't enough Americans earning more than $250,000 to finance the estimated $1.7 trillion price tag, reform would mean higher taxes for the middle class.
Favorable Response Rate in Patients Who Have Failed Prior Therapy.
|Powered by NeonCRM|